Literature DB >> 15223052

Pharmacological chaperones: potential treatment for conformational diseases.

Virginie Bernier1, Monique Lagacé, Daniel G Bichet, Michel Bouvier.   

Abstract

Increasing numbers of inherited diseases are found to result from mutations that lead to misfolded proteins. In many cases, the changes in conformation are relatively modest and the function of the protein would not be predicted to be affected. Yet, these proteins are recognized as "misfolded" and degraded prematurely. Recently, small molecules known as chemical and pharmacological chaperones were found to stabilize such mutant proteins and facilitate their trafficking to their site of action. Here, we review the recent published evidence suggesting that pharmacological chaperones represent promising avenues for the treatment of endocrine and metabolic diseases such as hyperinsulinemic hypoglycemia, hypogonadotropic hypogonadism and nephrogenic diabetes insipidus, and might become a general therapeutic strategy for the treatment of conformational diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223052     DOI: 10.1016/j.tem.2004.05.003

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  97 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

2.  GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors.

Authors:  Randa S Eshaq; Letha D Stahl; Randolph Stone; Sheryl S Smith; Lucy C Robinson; Nancy J Leidenheimer
Journal:  Brain Res       Date:  2010-05-16       Impact factor: 3.252

3.  Phosphorylation-dependent C-terminal binding of 14-3-3 proteins promotes cell surface expression of HIV co-receptor GPR15.

Authors:  Yukari Okamoto; Sojin Shikano
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

Review 4.  Protein misfolding disorders: pathogenesis and intervention.

Authors:  N Gregersen
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

5.  Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.

Authors:  Sayali A Ranadive; Baran Ersoy; Helene Favre; Clement C Cheung; Stephen M Rosenthal; Walter L Miller; Christian Vaisse
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-18       Impact factor: 3.478

Review 6.  G protein-coupled receptor sorting to endosomes and lysosomes.

Authors:  Adriano Marchese; May M Paing; Brenda R S Temple; JoAnn Trejo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 7.  The therapeutic potential of chemical chaperones in protein folding diseases.

Authors:  Leonardo Cortez; Valerie Sim
Journal:  Prion       Date:  2014-05-12       Impact factor: 3.931

8.  Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor.

Authors:  Nobuaki Hirota; Daisuke Yasuda; Tomomi Hashidate; Teruyasu Yamamoto; Satoshi Yamaguchi; Teruyuki Nagamune; Takahide Nagase; Takao Shimizu; Motonao Nakamura
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

9.  Plasma membrane expression of gonadotropin-releasing hormone receptors: regulation by peptide and nonpeptide antagonists.

Authors:  Ann R Finch; Christopher J Caunt; Stephen P Armstrong; Craig A McArdle
Journal:  Mol Endocrinol       Date:  2009-12-15

Review 10.  Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Trends Endocrinol Metab       Date:  2009-12-11       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.